Jan 17, 2023 7:00am EST Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study
Jan 11, 2023 7:00am EST Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board
Jan 09, 2023 7:00am EST Algernon Pharmaceuticals Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil
Jan 03, 2023 7:00am EST Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering
Dec 05, 2022 7:00am EST Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
Nov 16, 2022 7:00am EST Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study
Oct 24, 2022 7:00am EDT Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study
Oct 14, 2022 7:00am EDT Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit Molecule” to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference
Sep 21, 2022 7:00am EDT Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian Research Program
Sep 19, 2022 7:00am EDT Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF
